Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab Add-On Therapy in Acute NMOSD
NCT07410039Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chinese PLA General Hospital. Started Feb 2026; status: recruiting.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07410039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410039.